Kamada

Kamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. It operates through the Proprietary Products and Distribution segments. The Proprietary Products segment covers the development, manufacture, and sale of plasma-derived protein therapeutics products. The Distribution segment covers the drug products in Israel, which are manufactured by third parties. The company was founded by David Tsur and Ralf Hahn on December 13, 1990 and is headquartered in Rehovot, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Kamada reports robust earnings, eyes global expansion and clinical milestones

Kamada's strong financial performance, strategic acquisitions, and global expansion efforts position the company for continued growth and market success.
While facing challenges in maintaining growth momentum and operational efficiency, Kamada's focus on innovation and market expansion presents significant opportunities for future development.
Investors should monitor Kamada's progress in clinical trials, product diversification, and international market penetration to assess the company's long-term growth potential and market positioning.

Kamada secures $60M investment, targets 35% revenue growth in 2023

Kamada's Q1 2023 performance showed revenue and EBITDA growth, supported by strategic investments and regulatory approvals. While facing rising expenses and financial challenges, the company aims for significant revenue growth in 2023 through market expansion and trial acceleration.

Kamada (KMDA) reports strong Q2 earnings and secures $60M investment

Kamada (KMDA) delivered robust financial results in Q2 2023, with significant revenue growth and positive EBITDA performance.
The company's strategic investments, diverse product pipeline, and regulatory progress underscore its potential for future growth and market expansion.
Stable cash position, operational efficiency, and ongoing clinical advancements position Kamada favorably in the biopharmaceutical industry.
Overall, Kamada's Q2 performance and future outlook reflect a promising trajectory for sustained growth and value creation for shareholders.

Kamada reports robust Q3 earnings, eyes growth through clinical trials

Kamada's Q3 2023 earnings call highlighted strong financial performance, debt-free status, and strategic initiatives for future growth. The company's focus on product development, clinical trials, and board expertise positions it well for continued success and profitability.

Kamada reports robust 2023 earnings, eyes growth through strategic initiatives

Kamada's strong financial performance in 2023 and positive outlook for 2024 underscore the company's growth trajectory and market positioning.
While facing challenges such as rising operating expenses, Kamada's focus on innovation, market expansion, and strategic partnerships presents opportunities for sustained growth.
Maintaining a robust balance sheet and advancing key clinical trials reflect Kamada's commitment to financial stability, product development, and long-term value creation.

Kamada doubles profitability in Q1 2024, eyes revenue growth

Kamada delivered robust financial performance in Q1 2024, with doubled profitability and revenue growth driven by key products. The company's strategic initiatives, including product launches and clinical trial progress, position it well for future success. While facing cost pressures, Kamada's strong cash position and focus on innovation present opportunities for sustained growth.

Kamada excels in Q2, eyes global expansion and clinical milestones

Kamada's strong financial performance in Q2 2024 and the first half of the year, coupled with reaffirmed full-year guidance, reflect a positive growth trajectory and financial stability.
The company's strategic focus on organic growth, M&A activities, and clinical trials positions it well to capitalize on market opportunities and drive future revenue expansion.
While challenges such as dividend policy, regulatory timelines, and market competition exist, Kamada's proactive approach to business development and global partnerships underscores its commitment to sustained growth and innovation.

Kamada reports strong Q3 earnings, eyes growth in clinical trials

Kamada's Q3 2024 earnings call highlighted robust financial performance, increased guidance, and strategic initiatives driving growth and market expansion.
With a strong balance sheet, ongoing clinical trials, and expansion plans, Kamada is well-positioned to capitalize on market opportunities and sustain growth momentum.
While challenges such as market competition and integration risks exist, Kamada's proactive approach to innovation, partnerships, and operational efficiency bodes well for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioDelivery Sciences

Co-Diagnostics

Surface Oncology Inc

Viemed Healthcare

As of April 21, the GuruFocus All-in-One Screener, a Premium feature, found that the following guru-owned utilities have low price-earnings ratios. While some of them are great value investments, others may need to be researched more carefully, according to the discounted cash flow calculator.

5 Health Care Stocks Trading with Low Price-Earnings Ratios

It has been several years since we last did an in-depth piece on Israeli-based biotech concern Kamada. Early Wednesday, the company disclosed trial results on a candidate being evaluated as a potential treatment for COVID-19.

Checking Back In On Kamada

Kamada Ltd (NASDAQ: KMDA) has announced top-line results from its Phase 1/2 trial in Israel evaluating plasma-derived hyperimmune globulin (IgG) treatment for COVID-19. Kamada had announced the interim results from the study in September last year.

Kamada Reports Top-line Data Of Plasma-Derived IgG Treatment From Early-Stage COVID-19 Trial

REHOVOT, Israel, March 31, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced top-line results from its Phase 1/2 open-label, single-arm, multi-center clinical trial in Israel of the Company's anti-SARS-CoV-2 plasma-derived hyperimmune globulin (IgG) treatment for coronavirus disease (COVID-19). Interim results from this study were announced by Kamada in September 2020.

Kamada Announces Top-line Results from its Phase 1/2 Clinical Trial of its Plasma-Derived Hyperimmune Globulin (IgG) Treatment for Coronavirus Disease (COVID-19)

REHOVOT, Israel, March 09, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived biopharmaceutical company, announced today that Amir London, Chief Executive Officer, will present a corporate overview at the inaugural Jefferies Virtual Global Plasma Summit, being held on March 11, 2021.

Kamada to Present at the Jefferies Global Plasma Summit

Transaction Furthers Kamada's Strategic Objective to Evolve into a Fully Integrated Specialty Plasma Company

Kamada Announces the Closing of the Acquisition of the FDA-Licensed Plasma Collection Center from Blood and Plasma Research, Inc. in the U.S.

REHOVOT, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2020, with the U.S. Securities and Exchange Commission (the “SEC”).

Kamada Files Annual Report for the Year Ended December 31, 2020

Kamada's (KMDA) CEO Amir London on Q4 2020 Results - Earnings Call Transcript

Kamada (KMDA) delivered earnings and revenue surprises of -42.86% and -4.89%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Kamada (KMDA) Misses Q4 Earnings and Revenue Estimates

Shares of Kamada (NASDAQ:KMDA) decreased 1.6% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 69.23% over the past year to $0.04, which missed the estimate of $0.07.

Recap: Kamada Q4 Earnings

REHOVOT, Israel, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced financial results for the three and 12 months ended December 31, 2020.

Kamada Reports Fourth Quarter and Fiscal Year 2020 Financial Results, Recent Achievements and Corporate Development Activities

Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Kamada (KMDA) Q4 Earnings Expected to Decline

REHOVOT, Israel, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the fourth quarter and fiscal year ended December 31, 2020, prior to the open of the U.S. financial markets on Wednesday, February 10, 2021.

Kamada to Announce Fourth Quarter and Fiscal Year Ended December 31, 2020 Financial Results, and Host Conference Call on February 10, 2021

Transaction Represents Kamada's Entry into U.S. Plasma Collection Market and Advances the Company's Strategic Objective to Evolve into a Fully Integrated Specialty Plasma Company

Kamada Acquires FDA-Licensed Plasma Collection Center from Blood and Plasma Research, Inc. in Texas, USA

Award Recognizes Israeli Companies Working to Combat Coronavirus and the Damage of Future Pandemics Award Recognizes Israeli Companies Working to Combat Coronavirus and the Damage of Future Pandemics

Kamada Selected as a Winner of the Genesis Prize Foundation and Start-Up Nation Central Competition

REHOVOT, Israel, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: NBI). The annual re-ranking of the NASDAQ Biotechnology Index will become effective prior to market open on Monday, December 21, 2020.

Kamada Added to the NASDAQ Biotechnology Index

Let's see if Kamada (KMDA) stock is a good choice for value-oriented investors right now from multiple angles.

Should Value Investors Consider Kamada (KMDA) Stock Now?

Kamada Ltd. (KMDA) CEO Amir London on Q3 2020 Results - Earnings Call Transcript

Kamada (KMDA) delivered earnings and revenue surprises of 100.00% and 5.50%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Kamada (KMDA) Q3 Earnings and Revenues Beat Estimates

Earnings Preview: Kamada (KMDA) Q3 Earnings Expected to Decline

REHOVOT, Israel, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the third quarter ended September 30, 2020, prior to the open of the U.S. financial markets on Wednesday, November 11, 2020.

Kamada to Announce Third Quarter Ended September 30, 2020 Financial Results and Host Conference Call on November 11, 2020

We believe Kamada looks cheap, as there are long-tailed asset returns from the Takeda deal which the market may be overlooking. Recent retraction in Kamada's shares on the charts signals a potential dislocation in value and to today's trading.

Kamada Looks Cheap AS Takeda Deal Creates Value

The biotech specializes in plasma-derived protein therapeutics.

Kamada Will Supply COVID-19 Treatment to Israel

REHOVOT, Israel, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it has signed an agreement with the Israeli Ministry of Health (MoH) to supply its anti-SARS-CoV-2 plasma-derived hyperimmune immunoglobulin (IgG) product for the treatment of coronavirus (COVID-19) patients in Israel. The use of this investigational product will be regulated by the MoH.

Kamada Announces Supply Agreement with Israeli Ministry of Health for its Investigational IgG Product for COVID-19; Initial Order Expected to Generate $3.4 Million in Revenue in First Quarter of 2021

REHOVOT, Israel, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced that, following recent discussions with Takeda, it expects to receive approximately $25 million in revenues from the supply of GLASSIA® to Takeda in 2021.

News for Kamada Stock (KMDA)